Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 10,989 Shares

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) CEO Kevin Lee sold 10,989 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $6.46, for a total value of $70,988.94. Following the completion of the sale, the chief executive officer owned 618,996 shares of the company’s stock, valued at approximately $3,998,714.16. This trade represents a 1.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Kevin Lee also recently made the following trade(s):

• On Friday, January 2nd, Kevin Lee sold 10,325 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $6.80, for a total transaction of $70,210.00.

Bicycle Therapeutics Price Performance

BCYC traded down $0.04 during trading hours on Tuesday, reaching $6.57. 259,093 shares of the stock traded hands, compared to its average volume of 215,285. Bicycle Therapeutics PLC Sponsored ADR has a fifty-two week low of $6.03 and a fifty-two week high of $15.47. The company has a market cap of $455.76 million, a price-to-earnings ratio of -1.81 and a beta of 1.52. The firm’s fifty day simple moving average is $6.97 and its two-hundred day simple moving average is $7.42.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Thursday, October 30th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.09) by $0.24. Bicycle Therapeutics had a negative return on equity of 36.05% and a negative net margin of 884.51%.The company had revenue of $11.73 million during the quarter, compared to the consensus estimate of $8.25 million. On average, research analysts predict that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on BCYC shares. JMP Securities set a $12.00 target price on Bicycle Therapeutics in a research note on Friday, October 31st. Citigroup reiterated an “outperform” rating on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Royal Bank Of Canada reissued a “sector perform” rating and set a $11.00 price objective (down from $27.00) on shares of Bicycle Therapeutics in a report on Friday, October 31st. Citizens Jmp upped their target price on shares of Bicycle Therapeutics from $10.00 to $12.00 and gave the company a “market outperform” rating in a research note on Friday, October 31st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Monday, December 22nd. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $19.73.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BCYC. Armistice Capital LLC increased its position in Bicycle Therapeutics by 6.4% in the third quarter. Armistice Capital LLC now owns 2,978,000 shares of the company’s stock worth $23,050,000 after buying an additional 178,000 shares during the period. Long Focus Capital Management LLC grew its position in shares of Bicycle Therapeutics by 7.7% during the third quarter. Long Focus Capital Management LLC now owns 1,418,695 shares of the company’s stock worth $10,981,000 after acquiring an additional 101,402 shares during the last quarter. Moore Capital Management LP grew its position in shares of Bicycle Therapeutics by 66.7% during the third quarter. Moore Capital Management LP now owns 125,000 shares of the company’s stock worth $968,000 after acquiring an additional 50,000 shares during the last quarter. Citadel Advisors LLC increased its holdings in shares of Bicycle Therapeutics by 20.3% in the 3rd quarter. Citadel Advisors LLC now owns 189,027 shares of the company’s stock worth $1,463,000 after acquiring an additional 31,860 shares during the period. Finally, Ameriprise Financial Inc. lifted its position in Bicycle Therapeutics by 21.7% in the 3rd quarter. Ameriprise Financial Inc. now owns 14,972 shares of the company’s stock valued at $116,000 after purchasing an additional 2,668 shares during the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.